{"contentid": 488183, "importid": NaN, "name": "BMS\u00e2\u0080\u0099 latest Opdivo submission validated by EMA", "introduction": "US drugmaker Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its type II variation application for Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.", "content": "<p>US drugmaker Bristol Myers Squibb (NYSE: BMY) has announced that the European Medicines Agency (EMA) has validated its type II variation application for Opdivo (nivolumab) for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.</p>\n<p>The application is based on results from CheckMate -274, the first positive Phase III trial of an immunotherapy in this setting, which demonstrated increased disease-free survival with Opdivo versus placebo, regardless of patients&rsquo; PD-L1 expression levels.</p>\n<p>Opdivo was generally well tolerated in the trial, with a safety profile that was consistent with previously-reported studies in patients with solid tumors.</p>\n<p>Dana Walker, BMS vice president, development program lead, genitourinary cancers, said: &ldquo;Even patients who appear disease-free after radical surgery for muscle-invasive urothelial carcinoma are at a high risk for recurrence, with around half of patients having their cancer return.</p>\n<p>&ldquo;In the CheckMate -274 trial, Opdivo significantly reduced the risk of cancer recurrence or death, showing its potential to help address the need for safe and effective treatment options for this patient population. We look forward to working with the EMA towards the goal of bringing the first adjuvant immunotherapy option to patients with muscle-invasive urothelial carcinoma in the European Union.&rdquo;</p>\n<p>Opdivo-based treatments have now demonstrated efficacy in four Phase III trials in earlier-stage cancers, including bladder cancer, melanoma, esophageal/gastroesophageal junction cancer and non-small cell lung cancer.</p>", "date": "2021-03-29 15:01:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-29 14:50:35", "updated": "2021-03-29 15:28:29", "access": NaN, "url": "https://www.thepharmaletter.com/article/bms-latest-opdivo-submission-validated-by-ema", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "bristol-myers-squibb_large.png", "image2id": "bristol-myers-squibb_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Genito-urinary, Oncology", "topic_tag": "European Medicines Agency, Focus On, Regulation", "geography_tag": "USA", "company_tag": "Bristol-Myers Squibb", "drug_tag": "Opdivo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-29 15:01:00"}